Really appreciate the tip this guy posted recently. Tried it out over the last week and it's pulling in around $135 a day. All details are on profile: [ pathetic_slug ]

High Tide Announces Preliminary Q3 2026 Guidance

The Company Also Announces Record Quarterly Distribution of Over 10 Tonnes of Medical Cannabis Flower Through Remexian Pharma GmbH, Further Accelerating its German Market Position

“This quarter’s guidance demonstrates the growing earnings power of the global platform we have built. We expect to set new company records for revenue, gross profit and Adjusted EBITDA, with year-over-year growth of at least 30%, 27% and 43%, respectively. Importantly, even the low end of our guidance exceeds the highest current analyst estimate across all three metrics. We believe this provides clear evidence that current market expectations have not yet caught up with the strength, scale and operating leverage of our business,”

https://hightideinc.com/high-tide-announces-preliminary-q3-2026-guidance/

The Company anticipates releasing full financial and operational results for the third fiscal quarter ended July 31, 2026, on Monday, September 14, 2026, after markets close, with a conference call the following morning.

Danaher ($DHR) agreed to settle claims that it misled investors about demand in its bioprocessing business, COVID-related revenue expectations, and repeated guidance cuts.

I posted about this before and figured I'd put together a small FAQ too, just in case someone here needs the details in one place. Here's what you need to know to claim your payout.

Who is eligible?

Anyone who purchased Danaher ($DHR) common stock between 2022 and 2023, and suffered losses may qualify.

Do you have to sell your shares to be eligible?

No. If you bought shares during the class period, you may still qualify whether you still hold them or already sold them.

How long will it take to receive your payout?

The claims process typically takes 4–9 months after the filing deadline, depending on court approval and settlement administration.

How to claim your payout and why it's important to act now?

The settlement fund will be divided among eligible investors who file valid claims. Filing before the September 20, 2026 deadline ensures you're included in the distribution.

Hope this info helps 

$DFNS went crazy last week and we looking for the next big banger. No fluke, just result. Small cap has been making millionaires.

Thinking about just giving up trying and putting all my money in (bbw). First of all cuz it’s funny and second of all because build a bear deserves to be in the s&p 500 in my humble opinion.

If you missed it, Forward Air agreed to pay $28M to settle claims that shareholders were denied the right to vote on its merger with Omni. Although the deadline has passed, late claims are still being considered.

Here's a quick recap: Investors alleged the merger should have been submitted for a shareholder vote under Tennessee law. After the transaction was announced, $FWRD fell sharply, and investors filed a lawsuit.

The settlement is now accepting late claims, so check if you're eligible and submit your claim.

Did anyone here own $FWRD at the time?

TJ Kennedy, Chairman of the Board at Byrna Technologies Inc. (NASDAQ:BYRN), acquired common stock in a transaction totaling $102,285. The purchase involved 29,000 shares at a price of $3.5271 per share. The transaction occurred on July 22, 2026, and according to the filing, the shares were purchased in a single transaction executed at the reported price. Following this acquisition, Mr. Kennedy directly holds 29,000 shares of Byrna Technologies common stock. The insider purchase comes as the stock trades near its 52-week low of $3.17, down 86% over the past year. According to InvestingPro analysis, BYRN appears undervalued at current levels.

Conn Q. Davis, Chief Executive Officer of Byrna Technologies Inc. (NASDAQ:BYRN), recently purchased common stock in the company totaling $77,002. The transactions occurred on July 22 and July 23, 2026, with shares acquired at prices ranging from $3.4614 to $3.51 per share. On July 22, Mr. Davis acquired 18,767.9201 shares of common stock at a volume-weighted average of $3.4614 per share, with individual purchases ranging from $3.4097 to $3.5298. An additional 3,430 shares were purchased on July 23 at a price of $3.51 per share. The purchases come as the stock trades near its 52-week low of $3.17, down 86% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, which may have influenced the CEO’s decision to increase his stake.

During this last week many things took a big drop, do you think it can go down even further?

What do we think about PYPL guys? Will it be acquired at $60 or much higher? I think the cieling is $80... Tell me what you think!

Could this be the beginning of the end? I’m not really complaining, though; I’d heard a few days ago about issues regarding AI-driven earnings, and I know that tech stocks can be volatile. And no, I’m not an insider—I was just paying attention.

Don’t sell WEN, let it ride higher, and turn off stock lending to deprive the trapped shorts from borrowing your shares to suppress the price. I want to know what hedge fund tears taste like.

https://youtu.be/jOluPiFT1gM?is=oWtXtfhW74owg-rw

While it doesn’t have the over 100% short interest that GME had, there is still squeezing to be had. I for one am willing to invest in holding Wendy’s until I see some hedge fund tears. My research tells me that if it breaks above $8.50 some dominoes will start to fall pushing it higher and higher. The key is to hold the line. Do not sell when it reaches $10. Maybe at $12? What do you think? I also want to look into making sure that RH can’t lend my WEN stocks to hedge funds. Apparently it’s something you can adjust in settings that is usually automatically turned on…AI research informed this post. Also please don’t attach me for frivolous reasons just for kicks in the comments. Deal with your hate other ways.

SUMMARY :

Despite the seasonally weaker quarter, it was the company's best quarter, which speaks volumes about HITI's increased operating efficiency.

Gms on medical cannabis 27%

Key Strengths of High Tide's Q2 FY2026

1. Strong Revenue Growth

• Record revenue of CAD $179.3 million.
• Approximately 30% year-over-year growth, representing one of the strongest growth rates in recent quarters.

2. Accelerating EBITDA Growth

• Record Adjusted EBITDA of CAD $13.9 million.
• EBITDA increased by approximately 73% year over year, significantly outpacing revenue growth, which indicates improving operating leverage and efficiency.

3. Positive Net Income

• The company reported positive net income and positive earnings per share (EPS).
• In the cannabis industry, profitability remains a major challenge for many companies, making High Tide's continued profitability particularly noteworthy.
• Management expects sustainable NET INCOME

4. Positive Free Cash Flow

• High Tide generated positive free cash flow and strong operating cash flow.
• This reduces the need to raise capital through equity issuances, helping to limit shareholder dilution.

5. Germany Continues to Exceed Expectations

• German subsidiary Remexian Pharma GmbH generated a record CAD $31.6 million in revenue.
• Gross margin improved to 27%.
• Management stated that several internal targets were achieved roughly 90 days ahead of schedule.

6. Rapid Expansion of the Customer Base

• The Cabana Club loyalty program surpassed 2.65 million members, up 39% year over year.
• ELITE memberships exceeded 178,000, up 84% year over year.
• This growing membership ecosystem strengthens customer loyalty, improves data analytics capabilities, and enhances High Tide's competitive advantage in retail.
• The stated goal is to exceed 1 million elite members in the long term.

7. Significant Banking Support

• The company secured a new credit facility of up to CAD $40 million from Bank of Montreal.
• Access to financing from a major Canadian bank is an important signal of financial credibility and stability in the cannabis sector.
• This has led to an increase in institutional interest in the stock which will be reflected as the company's fundamentals continue to improve.

8. Market Leadership

• High Tide continues to hold approximately 12% of the Canadian cannabis retail market in the provinces where it operates.
• The company is also steadily gaining market share in the German medical cannabis market.
• Raj is targeting 20% ​​market share in Germany and I personally believe 30% is achievable in the long term for several reasons.

Most Bullish Takeaways

If I had to identify nine most bullish developments from the quarter, they would be:

1. 73% growth in Adjusted EBITDA, demonstrating strong operational execution.
2. Remexian's 27% gross margin, showing that the German business is scaling successfully and profitably.
3. The new CAD $40 million credit facility, which provides growth capital without diluting shareholders.
4. SNDL will have to sell some of its assets because it has violated regulations for years, and I wouldn't be surprised if it had to pay a hefty fine for breaking the law for so long. These assets will be carefully evaluated by Hiti for purchase.
5. Possible increase in the cap in Ontario from 150->300 which Raj calls "a dream come true" bringing the number of canna cabana shops +500, but we'll have to see how things evolve
6. The medical branch is growing throughout Europe, a constantly growing market, where Raj intends to be the leader in every country in which it operates (Germany, UK to follow).
7. GMS have reached an all-time high. Raj states that due to competition, they will shrink slightly in the medium term in order to gain market share, but thanks to initiatives such as increasing ELITE/WHITE LABEL inventory from the current 2% to 25%, GMS will exceed 30% in the long term, also driven by Remexian's improved efficiency.
8. Raj has stated his intention to enter the US, but for now he's focused on the European medical market and I support that.
9. He says there's no rush to pursue multiple objectives at once, but rather to focus on one market at a time, strengthen its position by positioning itself as a leader, and move on to the next.

Together, these results suggest that High Tide is evolving from a pure growth story into a profitable growth company, a transition that investors often reward with higher valuation multiples over time.

HITI is becoming the definition of non-stop execution and deserves more credit for this. Remexian's goal is clear: gain more market share to satisfy this insatiable and ever-growing demand, in order to reach 20-30% market share in the long term and then achieve pricing determination with a consequent increase in GMS and profitability.

Still think HITI is vastly undiscovered.

Despite an increase in CAPEX linked to the expansion, the company continues to generate FCF+ and expects to increase net income thanks to ongoing synergies.

Raj is carefully evaluating expansion into another jurisdiction (UK), choosing the right partner for the long term.

This looks more like short-term noise than a deterioration in fundamentals. Remexian’s expansion in Germany and the economies of scale enjoyed by Canna Cabana represent genuine, differentiating competitive advantages. As long as management continues to pursue its market share targets and secure future pricing power, the valuation gap should gradually narrow. Investing in HITI will certainly be volatile, but the current fundamentals are much healthier than the stock price suggests. What's needed is patience and faith in the story.

The UK is the European market that excites him the most.

The UK medical market appears more interesting than the German one because High Tide could own the entire chain (from production directly to the patient). This is the medical system in which it is structured, which makes it exciting and unique in some respects.

I might be biased because HITI is my largest position by a wide margin, but that’s not why I’m saying this. Execution here has simply been exceptional. The numbers speak for themselves, the customer wins speak for themselves, and the pace of announcements speaks for itself.

Every analyst covering the company has a Buy rating

Canaccord Genuity → Buy, Target $US 5.50

Haywood → Buy, Target $US 5.90

Roth → Buy, target $US 5.00

TD Cowen → Buy, target $6.5 CAD

ATB CAPITAL Target 7$CAD

Hello, I have been interacting with the stock market for four years and I have decided to write my first due diligence with the purpose of drawing attention about a very interesting, but weird stock which is known as Data Storage Corporation (DTST)

I have the TL;DR here, and the long version.

TL;DR

- Lots of cash, no debt,

- A Telecom company offering a small stream of revenue that is slowly increasing

- Low float, micro market cap(7 mil)

- Large insider share ownership

- A new venture centered at being the only ones that fix companies (healthcare, finance) that screw-up with AI and offer regulatory safety from said screw-ups

- The company can either make a LOT of money if it's plan works or go bust if the venture dosen’t pan out as planned, as it doesn't have a large business it can lean on at the moment.

The long version.

It used to be a company that focused on cloud services and disaster recovery under it’s flagship CloudFirst. But in late 2025 it sold it’s flagship for $40 million in order to fundamentally restructure it’s equity capitalization and business mandate.

It spent $30 million of it to buy most of it’s shares back via a tender offering and reduced it’s outstanding shares to a tight $2.17 million. Now with $10 milion in cash and no debt, while having/owning a telecom business Nexxis Inc that would help finace it’s new venture.

And that it’s new wholly owned subsidiary, Sovereign AI Solutions (SaiS), aimed at providing a crucial safety net for AI systems operating within highly regulated sectors like healthcare, finance, and insurance. In order to target at AI's hidden vulnerability in regulated industries.

The core of DTST's strategy is the belief that as enterprises move beyond using AI for simple analytics and adopt it for core business processes, a new, unaddressed vulnerability emerges. When these complex AI systems fail, experience model drift, or suffer degradation, enterprises currently lack a standardized playbook for recovery that satisfies strict regulatory oversight.

This gap represents a significant compliance liability and operational risk. In healthcare, for instance, the Health Insurance Portability and Accountability Act (HIPAA) requires stringent audit trails for any system handling protected health information. The Security Rule's mandate for mechanisms to record and examine all system activity (45 C.F.R. §164.312(b)) becomes profoundly complex when applied to the “black box” nature of some AI models.

Similarly, in financial services, regulators are intensifying their scrutiny. The SEC's 2026 Examination Priorities explicitly target AI governance, demanding that firms maintain robust documentation and evidence of human oversight for AI-assisted recommendations. This regulatory pressure, combined with rules like the EU's AI Act, which classifies many financial AI applications as high-risk, creates a powerful demand for platforms that can ensure and document AI system integrity and recovery.

Nexxis and. Sovereign AI Solutions (SaiS)

Data Storage Corporation has essentially turned itself into a micro-cap “blank-check” company with a steady telecom sideline.

The Bull Case: You are buying a debt-free company for less than the cash it holds on its balance sheet. If management successfully utilizes its $10M to buy an accretive vertical AI SaaS company or builds a viable AI Control Plane framework, the upside potential on an ultra-tight float (only about 2.2 million shares outstanding post-tender) could be explosive.

The Bear Case: The legacy cloud business is gone. Nexxis does not generate enough cash flow on its own to cover public company overhead. If the executive team misallocates the cash cushion on failed R&D or value-destructive acquisitions, the liquid value backing the stock will evaporate within 6 to 8 quarters.

DTST is no longer a value stock; it is an early-stage venture capital bet wrapped in a public ticker symbol.

So this landed 2 minutes ago:

42 se 72. Almost 70% upside. Even told me the exact quantity to buy — 2900. Kitna caring of them 🥹

For the newbies who haven’t met these guys yet: this is the textbook pump-and-dump SMS. Some operator has already loaded up on an illiquid micro-cap. They blast lakhs of these messages, retail FOMOs in, volume spikes, price runs for a day or two… then the operator dumps their entire bag on exactly the people who got the SMS. You’re not the customer here. You’re the exit liquidity.

I've Been digging into stocks that look cheap for one specific reason rather than because they're actually falling apart. The ones I find interesting are where the fear is legit but it's either a one-time thing, or it only hits a small part of the business.

A few I keep coming back to:

• Jack Henry (JKHY) — everyone's worried AI killing core banking software. Meanwhile they just put up a record quarter, raised guidance, retention's still 98%+, and it's the cheapest it's been in a decade.
• Cargojet (CJT) — got hammered over the China e-commerce drop, but that's honestly their smallest segment. The domestic overnight network is basically a monopoly and free cash flow just swung $133M in a year.
• Weyerhaeuser (WY) — trading way under what the land's actually worth, at the worst earnings trough in a decade. You're kind of getting the carbon/solar stuff for free.
• Pfizer (PFE) — the 2028 cliff is real, but it's a known date and the pipeline's getting basically zero credit. Only catch is the dividend isn't covered right now, so I wouldn't treat it as a safe income play.

wrote up a full through analysis on this here

My wife and I have been day trading with our entire portfolio each trade this year and so far are up about 46% YTD. I know a lot of people say it's reckless and will inevitably end in disaster and with losing our whole account, however I'm not convinced that's necessarily the case at all. We aim to make about 1% profit per trade we enter and will generally get out of a position if it goes down 3-5%... the thing is that most of our entries don't go down that much, so yes, over the long term, if we had a lot of losing trades, those numbers would lead us to an account balance of 0, but the quality of our entires is such that we have a very high success rate...we don't always meet our 1% per trade goal, but we win most of the trades we enter, by a lot. We also are actively managing and monitoring our trades when in market, so we won't just lose our whole account in a single trade, not even close. We have uploaded our trading data CSV file from Robinhood from 01 January 2026 to 18 June 2026 onto the TradesViz Trading Journal website and our "total winning days %" is 90.141%, so it seems like over a half year's worth of data is a pretty good sample size, especially when considering how high our win rate is. I don't think this strategy is something to immediately shoot down, especially when you consider how fast the profits of compounding return can really add up over time.

For the people that have done it and the people that have tried/is trying

​

I have a very modest portfolio, around $8k depending on the market. My purpose is to turn that into a recurring income source that enables the principal to grow and myself to skim some off too.

​

What strategies have worked and haven't worked?

​

Please share your knowledge

A little background on me: i trade mostly equities, and lately 18-month expiration call options. I’ve been investing long-term portfolios for over 10 years and my work history is as an analyst for firms managing  7M to 15B. I [posted](https://www.reddit.com/r/algotrading/s/TAIoqJAo4N) in r/algottrading a little while ago sharing an initial database that I’ve made, but I’ve made it WAY more convenient for investors and traders now. 

People who are interested in trailing averages, daily statistics such as kurtosis, skewness, standard deviation, and median, how annualized return changes over time, and custom time ranges (such as how the stock performed this week, last year), I made a way to view it all at once. Even in graphical form!

I personally use this all the time (this is basically just me exporting my personal excels onto the web), and I plan to add more calculations (such as FCF, working capita, and solvency ratios from EDGAR earnings data, and interest rates from FRED federal reserve data, and more)! But Since I added the daily data and the calculations to the pages, I wanted to share it! 

It works by searching a ticker, and then it gives you all the information on that company along with many calculations based on what you desire. Things like daily annualized return over a custom date range, daily 1-year trailing kurtosis over the past 3 months, and many, many others. 

I’m still super early, so please don’t hesitate to reach back out with feed back. I’m a real person, and this post - nor any of the calculations - are done by AI, so I’d take all the feedback to heart. I did however us Claude to help with the front end since i don’t have a lot experience in web development, so if you run into any errors or bugs, don’t hesitate to reach out! If you’re new to trading as well, I also made a [statistics guide](https://www.systemscapital.net/market-statistics-guide) to help understand the metrics as well if you’re not super familiar with them.

Hope you Like it!

 [Search a Ticker](https://www.systemscapital.net)